ABSTRACT Motivation: MALDI mass spectrometry is able to elicit macromolecular expression data from cellular material and when used in conjunction with Ciphergen protein chip technology (also referred to as SELDI-Surface Enhanced Laser Desorption/Ionization), it permits a semi-high throughput approach to be taken with respect to sample processing and data acquisition. Due to the large array of data that is generated from a single analysis (8-10 000 variables using a mass range of 2-15 kDa-this paper) it is essential to implement the use of algorithms that can detect expression patterns from such large volumes of data correlating to a given biological/pathological phenotype from multiple samples. If successful, the methodology could be extrapolated to larger data sets to enable the identification of validated biomarkers correlating strongly to disease progression. This would not only serve to enable tumours to be classified according to their molecular expression profile but could also focus attention upon a relatively small number of molecules that might warrant further biochemical/molecular characterization to assess their suitability as potential therapeutic targets. Results: Using a multi-layer perceptron Artificial Neural Network (ANN) (Neuroshell 2) with a back propagation algorithm we have developed a prototype approach that uses a model system (comprising five low and seven high-grade human astrocytomas) to identify mass spectral peaks whose relative intensity values correlate strongly to tumour grade. Analyzing data derived from MALDI
INTRODUCTION

Proteomics and biomarker identification using MALDI-based mass spectrometry systems
The identification of phenotypic expression patterns that correlate strongly to a defined pathological condition would undoubtedly represent a significant step towards the development of novel therapies in which these molecules might serve as clinical targets (Fung et al., 2001) . Techniques that involve molecular profiling are not c Oxford University Press 2002 only confined to identifying macromolecules (e.g. peptides/proteins) that could form the basis of new treatment regimes, they can even be applied as a novel methodology for the pathological classification of diseased tissue such as cancer (Sørlie et al., 2001) . Ultimately extrapolation of these techniques may even permit the development of assays capable of accurately predicting patient response outcomes for particular forms of therapy. This is extremely desirable as it would (a) expedite the rate at which an objective clinical response could be ascertained, (b) direct clinical management in a patient specific manner and (c) identify candidates that might serve as therapeutic targets.
Matrix Assisted Laser Desorption/Ionization (MALDI) Mass Spectrometry (MALDI-MS) is an extremely sensitive analytical tool that will detect macromolecular ionic species (e.g. peptides/proteins) to approximately high attomole/low femtomole concentrations (Kussman and Roepstorff, 1998; Yates, 1998) . As such it can facilitate the acquisition of phenotypic expression patterns ('phenomic fingerprints') from limiting amounts of tissue (e.g. that obtained using micro/macro-dissection- Paweletz et al., 2000) . If used in conjunction with Ciphergen's 'protein chip' technology (also referred to as SELDI; Surfaced Enhanced Laser Desorption/Ionization), phenomic fingerprinting can be conducted in a semi-high throughput manner in relation to sample preparation, analysis and data acquisition (Cai et al., 2001; Vlahou et al., 2001; Davies, 2000; Fung et al., 2000; Paweletz et al., 2000; . Analytical methodologies such as this would help to identify peptides and proteins that might serve as clinically relevant molecular targets (e.g. biomarkers for disease progression and/or therapeutic targets) and as such provide a means to analyze the proteomes (the total complement of proteins) for any given cell. The number of peptides/proteins/complex polymers available for analysis from any given sample can range between 8000 and 10 000 individual data points (for M/Z values between 2 and 20 kDa this paper). To identify clinically significant biomarkers we believe that the use of a relatively large data set (e.g. 100 individual patient samples) would be warranted (and thus increase the degrees of freedom for making conclusions regarding statistical significance), however due to the vast array of data that would have to be screened to identify these ions, the development of first generation computer algorithms capable of analyzing the relative intensity data from MALDI-MS based systems is an absolute requisite. In order to achieve this goal, we have implemented the use of Artificial Neural Networks (ANN) to parameterize macromolecular ion expression by implementing a 'model' system involving low-and high-grade astrocytoma tissue and asked whether ions could be identified whose expression patterns correlated to tumour grade. Although the system was developed using SELDI-MS data, the process can be applied equally to any mass spectrometry systems (including other MALDI instruments) that generate a profile of mass spectral peaks in conjunction with relative intensity data. If successful, this approach could provide the basis for a larger and more detailed study in which biomarkers to specific clinical correlates would be ascertained directly at a molecular rather than a cellular level (as is currently the case with conventional histopathology).
Artificial neural networks with pattern recognition capabilities
ANNs have been applied to a number of diverse areas for the identification of 'biologically relevant' molecules, including pyrolysis mass spectrometry (Goodacre and Kell, 1996) and genomic microarraying of tumour tissue (Khan et al., 2001) . We have utilized a Multi-layer Perceptron (MLP) ANN with a back propagation algorithm for the analysis of SELDI Mass Spectrometry (SELDI-MS) data. It is well known that this type of ANN is a powerful tool for the analysis of complex data (Desilva et al., 1994; Balls et al., 1996; Wei et al., 1998) , containing a high level of background noise and can be used to identify the influence of many interacting factors (Kothari and Heekuck, 1993 ) that makes it highly suitable for the study of first generation SELDI-MS-derived data. ANNs can produce generalized models with a greater accuracy than conventional statistical techniques in medical diagnostics (Tafeit and Reibnegger, 1999; Reckwitz et al., 1999) without relying on predetermined relationships as in other modelling techniques.
ANNs in parameterization
A number of parameterization methods have been developed for the identification of the strength of influences on modelled ANN systems. The simplest methods are based on the analysis of weights of the trained ANN model to determine the strength of an input parameter's influence (Balls et al., 1996) . This method provides information that allows ranking of the importance of inputs and identification of interactions between input parameters, in relation to the outputs (Balls et al., 1996; Roadknight et al., 1997; Ball et al., 2000) . More advanced approaches, based on the change in performance (RMS error) of an ANN model that give an indication of the interactions between inputs, have been developed by the authors (Ball et al., 2000) . Determining important influences on the system being modelled allows the development of simplified and more generalized models by removal of inputs and input combinations with no influence. This technique can also be used to parameterize influences on a sub-set of data, for example outliers, data from different sources or different subpopulations.
Experimental approach
To determine whether ANNs might be applied to the identification of biologically relevant ions using SELDI-MS, we have developed a model system using a cohort of low-and high-grade astrocytoma tumours and determined whether molecular ions could be identified whose relative intensity pattern correlated strongly to tumour grade. The use of a small sample size was considered prudent, as it would elicit preliminary evidence regarding the feasibility of such an approach for the identification of biomarkers from larger data sets (e.g. n = 100).
METHODOLOGY
Tissue preparation
Astroglial tumours were graded using the Daumas-Duport (St Anne/Mayo) system (Daumas-Duport et al., 1988) where there are four grades, together with the WHO criteria for glioblastoma (Burger, 1995) . The grade equals the number of positive criteria +1, up to grade 4. The criteria are, nuclear atypia, mitoses, endothelial proliferation and necrosis. For an astroglial neoplasm to be classified as a glioblastoma in the WHO classification, there must be necrosis present, whereas some anaplastic astrocytomas, Dumas-Duport grade 4, do not show necrosis. Two sequential 10-15 µm frozen tissue sections were cut for each tumour (section thickness was gauged around this mark. Precise measurements concerning tissue thickness are difficult to ascertain due to the absence of immobilizing reagents such as paraffin (this could not be used for fear of creating protein modifications and hence artefacts)). The first section was stained with haematoxylin and eosin to determine tumour grade, purity and viability. Areas of tissue containing at least 75% tumour cells were macro-dissected (surface area approximating 7.5 mm 2 ) from the same area within the second unstained section. The tissue was placed directly into 30 µl of homogenizing buffer (9.5 M urea, 2% CHAPS, 1% DTT) for 15 min at room temperature with agitation to facilitate cell lysis and protein extraction. Homogenates were frozen at −80 • C prior to SELDI analysis.
SELDI mass spectrometry
Ciphergen H4 protein 'chips' (containing long chain (C-16) aliphatic hydrocarbon chains that bind proteins by reverse phase interactions) were loaded with 2 µl of 50% acetonitrile and 5 µl of cellular homogenate and exposed to the chip surface for 10 min at room temperature in a humid environment (to prevent drying out). Homogenates were then removed and the chip surface washed using 10 µl of water three times. The washes serve to remove non/low affinity bound molecules in addition to any residual urea. The surface was dried and 0.8 µl of a saturated solution of sinapinic acid added (Ciphergen Biosystems Inc.). The 'matrix' functions to absorb the energy of the laser and promote desorption/ionization of the retentate. Chip analysis was conducted at maximum laser intensity and 'phenomic fingerprints' derived from an average of at least 13 acquisitions per tumour sample. Each acquisition was composed of an average of 5 data collections and each data set therefore consisted of the mean spectrum from a minimum of 65 transients. Generation of m/z values were performed using external calibration. Measurements were taken in 4 nanosecond increments (expressed in microseconds). The following formula was adopted to calculate time of flight (t) and mass : charge ratio (m/z): The maximum error for mass accuracy using external calibration has been determined to be 0.1% (Ciphergen Biosystems)). For lower molecular mass ions, mass values were rounded up to the nearest Dalton to facilitate easy data manipulation. Data derived from SELDI-MS was exported directly into Microsoft Excel spread sheets for ANN analysis as a mass/intensity profile.
Data pre-treatment
Prior to data analysis and modelling, the data was split up into a number of blocks. The first incorporated m/z values from 100 Da to 2 kDa the next from 2 to 5 kDa and the remainder in 5 kDa blocks up to 20 kDa. Each of these blocks was used to train a separate ANN model to predict tumour grade.
ANN model development
This study used a three-layer MLP ANN with a backpropagation algorithm and a sigmoidal transfer function (Rumelhart and McClelland, 1986) . The models used a constrained architecture approach, limiting the hidden layer to only 2 hidden nodes (feature detectors). This ensured the developed models were parsimonious giving a clear representation of the key masses to the model.
Training was conducted to convergence on the training data, i.e. the RMS error reached a minimum value. Convergence was determined by a failure of the model to improve for 1000 training events. Test and validation data were not applied in this preliminary study, as its purpose was to test the principle that potential biomarkers could be identified from a data set with a large number of variables. Validation would be conducted at a later date if results indicated potential biomarkers could be identified and the approach warranted the generation of the large data sets.
Weightings analysis
Optimization of the input parameters to the ANN models was conducted in a two-stage process of parameterization and removal. In the first stage the weightings of the trained models for each block were analyzed (Balls et al., 1996; Ball et al., 1998 Ball et al., , 2000 .
ANN analysis stage 1: screening for noise removal
For each block, multiple sub-models (15) were trained using the same data set, however different random initialization weights were selected. For each sub-model the performance was monitored, Root Mean Squared (RMS) error calculated manually and the success of prediction determined. Success was defined as correct grade prediction for all cases using a cut off error value of 0.5. For models successfully predicting tumour grade, weightings analysis was conducted to determine the strength of influence for each of the molecular ions and based upon this, ranked according to their relative importance value.
ANN analysis stage 2: screening for key indicators
From the weightings analysis performed in Stage 1, mass spectral peaks having a relative importance of greater than 0.0008 were selected from each block. This arbitrary value was selected to reduce the number of inputs and select the more important ions from background noise. The selected ions were combined into a single ANN model having 550 inputs. This model was trained as with previous models in Stage 1. The RMS error was determined manually and weightings analysis conducted. Molecular ions were ranked based on their relative importance value and the top 50 were selected from this model for further analysis in Stage 3.
ANN analysis stage 3: identification of 'interactions' for key molecular ions
Stage 3 analysis facilitated the identification of a minimum number of ions capable of accurately defining tumour grade (based upon relative intensity patterns between low and high-grade astrocytoma), in addition to identifying 'interactions' occurring between these masses. This was achieved in a stepwise approach similar to stepwise regression (Ball et al., 1998) in which a number of submodels were trained. These models utilized the top 50 mass spectral peaks identified in Stage 2 possessing the highest relative importance values for their ability to accurately predict tumour grade. Of the sub-models with single inputs, the ion producing the lowest RMS error was selected for further training. Next, all of the remaining inputs were added in a sequential manner to the first input creating a second round of 49 two-input sub-models. These were trained as before and the model with the best performance for predicting tumour grade was selected.
Next a three input model was trained, and so forth. This process was repeated until no significant improvement occurred in the performance of the model (decrease in RMS error of less than 1%).
RESULTS
SELDI mass spectrometry data
Phenomic fingerprints were derived from 5 low and 7 high-grade astrocytomas. The mass/intensity data is expressed in a 'gel-type' format where intensity is represented by bandwidth rather than vertical height of the 'y' axis ( Figure 1 ). The data shows that mass-intensity profiles could be obtained reproducibly from frozen tissue sections and as such the data was deemed to be of sufficient quality for ANN analysis. The m/z data for each sample was exported directly into Microsoft Excel prior to parameterization by ANN. Da (number of data points present within this mass range are between 8000 and 10 000 for any given sample). The standard errors for relative importance were calculated to be less than 5% of mean value, suggesting that the ANN was capable of finding an optimal solution for predicting tumour grade irrespective of the weighting that was initially applied to the mass spectral peak. In order to simplify the model and find the most significant ions capable of predicting tumour grade, molecular ions derived from Stage 1 analysis were placed in descending order of relative importance and the top 550 ions (as Fig. 1 . SELDI mass/intensity spectra derived from low (L1-L5) and high-grade (H1-H7) astrocytomas. The data is presented in a 'gel' type format for ease of viewing. Molecular mass (Da) is presented on the x-axis. Intensity has been translated from a vertical y-axis to bandwidth (an example of peak width is shown by band 'A' in sample L2. Band 'A' has a relative intensity of 6 and an integrated peak area of 867). A representative profile of molecular ions ranging from 10 000 to 14 000 Da is shown.
measured by their relative importance) were taken for additional Stage 2 analysis.
Stage 2 results-random initialisation of weightings for the top 550 mass spectral peaks derived from Stage 1
To simplify the process of predicting tumour grade and identify key molecular ions whose relative intensity pattern correlated strongly to tumour grade, it was essential that the number of molecules be reduced from approximately 80-100 000 to just a few hundred. To achieve this goal, we chose an arbitrary value of 550 mass spectral peaks having the highest relative importance values (as ascertained from Stage 1 analysis). These ions were then combined in a Stage 2 model and relative importance values determined from 15 sub-models in which random initialization values were assigned to each sub-model. standard errors derived for all peaks were less than 5% of the mean value. This would suggest that the ANN was capable of finding an optimal solution for predicting tumour grade using relative intensity data, irrespective of the weighting that was initially applied to the mass spectral peak. Ions were then ranked in descending order of rela-tive importance values and the top 50 ions with the highest relative importance values were taken for Stage 3 analyses (data not shown).
Stage 3 results-creation of sub-models to determine the minimum number of mass spectral peaks capable of predicting tumour grade (i) 'Mass clustering.' Table 1 represents the top 50 charged masses derived from Stage 2 analyses in conjunction with their relative importance values. Using molecular mass as a basis for grouping these ions, it was evident that 8 sub-groups could be established and for some of these groups (e.g. 3626 Da), 16 ions had mass values extremely close to each other. There are a number of possible explanations that might account for 'mass clustering' including analytical variation (mass averaging), mass accuracy (external calibration can produce inaccuracies of up to 0.1% compared to 0.02% with internal standards (Ciphergen Biosystems) and possibly isotopic distribution (Dass, 2001) . As all data points derived from SELDI-MS are treated as independent variables i.e. no prior association is assumed between any molecules it is interesting to note that from a total data set of approximately 100 000 to 120 000 values (derived from 5 low and 7 high grade astrocytomas spanning a range of 0-20 kDa), molecular ions that are deemed to be highly significant in predicting tumour grade are often 'composite groups' that focus around a given molecular mass.
(ii) 'Associations' between molecular ions. To ascertain the therapeutic potential of any molecular biomarker, it would be necessary to first isolate, identify and characterize (if unknown) the molecule. To undertake a program of studies such as this would undoubtedly require a substantial investment in time and resources. It is essential therefore that any ion chosen for further characterization should have the highest confidence associated with it for having significant clinical potential. To develop computational approaches that might increase the probability of identifying ions with such requisites, we have implemented an 'additive' approach in which molecular ions are taken individually from the top 50 mass spectral peaks derived from Stage 2 analysis and are used to predict tumour grade. It is envisaged that such a stepwise procedure would enable a minimum number of key molecular ions to be identified whose changes in relative intensity correlate strongly to tumour grade and consequently might suggest either a direct or indirect role in the progression of tumours from low to high-grade astrocytoma. The ion eliciting the lowest error value for grade prediction ('one-ion model') would then be used in combination with each of the remaining 49 other ions and the process of predicting tumour grade for all 12 samples re-calculated. The model producing the lowest RMS error value for predicting grade (based upon the intensity profiles of two ions) would be selected to form the basis of a third round of analysis with the remaining 48 ions. This iterative process was repeated until no further significant decrease in RMS error occurred. Using this strategy, the lowest RMS value obtained (0.3603) for a single molecular ion was derived from the 13 454 Dalton mass peak-the individual error values derived for all 12-tumour samples using this molecular ion to predict tumour grade are presented in Table 2 . It is interesting to note that based upon the relative intensity data for one single ion, the ability to predict tumour grade is approximately 64%. Ion 13 454 was then combined with each of the remaining 49 other ions and RMS values calculated. Using a 'two-ion' model for predicting tumour grade, it was established that the lowest RMS error (0.0628) was obtained using molecular ions 13 454 and 13 457 (Table 3 ) resulting in 93.7% accuracy for predicting tumour grade. A 'three-ion' model revealed that the lowest RMS value obtained (0.0214) was derived using ions 13 454 + 13 457 + 14 287 (Table 4 ) resulting in 97.9% accuracy for predicting tumour grade. Finally a 'four-ion' model produced a RMS value of 0.0162 using charged mass 13 459 (Table 5 ) with no significant increase in accuracy for grade prediction (98.4%). No further rounds of addition were carried out. Mass/intensity values for charged masses 13 454, 13 457, 13 459, and 14 287 Using this sequential method to predict tumour grade, it was interesting to note that three of the four ions identified using this combinatorial approach had mass values within 5 Da of each other (13 454, 13 457 and 13 459 Da). An examination of the relative intensity values for all ions suggested all had a reduction in relative intensity as astrocytomas progress from low-to high-grade (Figure 3 ). For two of these molecular ions (13 454 and 13 457 Da) the reduction in intensity as tumours progressed to high-grade was statistically significant. Based upon this data one might speculate that because mass spectral peaks 13 454, 13 457 and 13 459 are responding in a biologically similar manner (i.e. relative intensity is being down-regulated as tumours progress from low-to high-grade) and due to their extremely close mass values, it is plausible that they might in fact be isotopic variants of the same ion. This latter point could only be confirmed however by isolating and characterizing each charged species. Based upon this stepwise procedure, it is evident that molecular ions can be rapidly identified whose relative intensity profiles change during tumour progression from low-to high-grade astrocytoma and that for two of these ions, the changes are statistically significant. Finally, the changes in relative intensity for these ions allows tumour grade to be predicted to an accuracy of greater than 98% using this model data set. It is suggested that these algorithms can provide the basis for a larger study in which training, validation and test data can be applied to identify molecular ions whose relative intensity profiles correlate accurately to clinical parameters such as tumour staging.
DISCUSSION
The ability to identify biological molecules that might serve as novel therapeutic targets for disease treatment or as biomarkers in predicting clinical outcomes could have profound effects upon the clinical management of cancer patients. MALDI based mass spectrometry such as SELDI, can facilitate the analysis of cellular peptides/proteins/polymer complexes in a semi-high throughput manner. For any given sample, the analytical phase can generate a spectrum of between eight and ten thousand data points from macro-dissected tumour tissue (using a mass range of 2-15 kDa-this paper). To establish whether ANNs have potential to identify clinically relevant biomarkers derived from SELDI data, we have developed a model system that utilizes crude cellular homogenates derived from low-and high-grade astrocytoma and asked whether molecular ions could be identified whose relative intensity profiles correlate strongly to tumour grade. Using mass ranges from 0-2000, 2001-5000, 5001-10 000, 10 001-15 000 and 15 001-20 000 Da, mass spectral peaks were identified that were important in predicting tumour grade. For each group, analyses were repeated 15 times using different random initialization values of the ANN and an optimal solution sought for each. Analysis of the 15 sub-models indicated a standard error less than 5% of the mean value for relative importance (suggesting that an optimal solution had been found) and molecular ions with a value of 0.0008 or higher were considered as potential candidates for Stage 2 analysis. These ions were ranked in descending order with the top 550 molecular species being used in a Stage 2 model. In accordance with Stage 1 modelling, each ANN sub-model was initialized with 15 different random weightings and an optimal solution was sought. Standard errors for relative importance values were less than 5% of the mean value suggesting that an optimal solution had been found irrespective of the initial weighting value assigned to the ANN. The top 50 molecular ions having the highest relative importance values were then selected and used in Stage 3 'association' models to determine the minimum number of ions capable of accurately predicting grade and whether these ions if used in combination with each other could further increase the ability of the ANN to accurately predict tumour grade. Using molecular mass to sub-divide these ions, it was interesting to note that 8 sub-groups could be established. For groups comprising five or more molecular ions, the standard deviation from the mean mass value was 6 Da or less and the range of values extended from 14 Da (2119 group) to 20 Da (3626 group). The spread of masses could be attributed to a number of factors that include both analytical variation (each read is an average of 65 transients), mass accuracy (external calibration can produce inaccuracies of up to 0.1%), amino acid substitutions (if the ions represent peptides/proteins) and possibly isotopic distribution. To identify potential 'relationships' or 'associations' (no direct association is assumed however) between the top 50 molecular ions possessing the highest relative intensity values, we conducted a stepwise procedure to determine (a) which ions (based upon their relative intensity profiles) could accurately predict tumour grade and (b) which combination of ions would act as the most accurate biomarkers for predicting tumour grade in this model system. A stepwise procedure (similar to stepwise regression; Ball et al., 1998) was utilized in which molecular ions were taken in isolation ('one-ion' model) and RMS error values calculated for predicting the grade of all 12 tumour specimens. The ion with the lowest error (i.e. most accurate) was identified as mass 13 454 Da and could predict grade to an accuracy of 64%. Using a 'two-ion' model involving molecular ion 13 457, the ability to predict tumour grade for all 12 samples had now increased to 94%. Both ions show a significant down-regulation as tumours progress from low-to high-grade astrocytoma and due to the limits of mass accuracy and data averaging we believe that they may represent the same molecular ion. Using three molecular ions, the ability to predict tumour grade increases by only 3%, with a four-ion model producing no significant rise in accuracy of prediction (an increase of 0.5%). In the absence of additional studies, it cannot be ascertained whether the reduction in relative intensity exhibited by molecular ions 13 454 and 13 457 represents a true down-regulation in ion concentration or an artefact of the system in which additional molecules (present in the high-grade astrocytoma extracts) suppresses the desorption and ionization of these molecules.
Future developments
The use of larger cohorts of material would permit candidate ions to be validated as biomarkers associated with increased tumour grade. In addition this methodology could be extrapolated to test its ability to predict the tumour grade of validation (i.e. unseen) data and its ability to 'generalize' ascertained. Optimization of SELDI-MS data generation is required e.g. in-situ sample clean up by washing the sample with a specified wash solvent followed by analysis of the washes to detect higher mass species and possibly minimize suppression effects. Finally, the use of laser capture microdissection would help to ensure that tissue samples used for proteomic analysis are of extremely high purity (e.g. 95-99%) and that the amount of cellular material used is consistent between preparations.
CONCLUSION
We have used a model system to establish whether ANNs could rapidly identify molecular ions of potential interest from a total data set of between 100-120 000 data points derived from SELDI mass spectrometry data. Using this model we have been able to identify at least two molecular ions within a 3 Da mass range of each other that are significantly down-regulated as astrocytomas progress from low-to high-grade. No prior association between molecular ions is assumed when identifying candidates whose relative intensity profiles might be strong indicators for tumour progression. It is interesting to note therefore that from an initial cohort of 100-120 000 data points, the ANN identified two molecular ions whose masses are within 3 Da of each other and whose relative intensity profiles are down-regulated in a statistically significant manner. It is suggested that application of this bioinformatic approach to larger cohorts of patient material could lead to the identification of biomarkers whose relative intensity profiles accurately correlate to clinical parameters such as tumour staging and possibly events predicting patient responsiveness to particular forms of therapy.
